Evia Bio Revenue and Competitors
Estimated Revenue & Valuation
- Evia Bio's estimated annual revenue is currently $1.6M per year.
- Evia Bio's estimated revenue per employee is $77,500
Employee Data
- Evia Bio has 21 Employees.
- Evia Bio grew their employee count by 75% last year.
Evia Bio's People
Name | Title | Email/Phone |
---|---|---|
1 | CSO & Founder | Reveal Email/Phone |
2 | COO | Reveal Email/Phone |
3 | Director Education & Community Development | Reveal Email/Phone |
4 | Director Operations | Reveal Email/Phone |
5 | Senior Scientist | Reveal Email/Phone |
6 | Researcher | Reveal Email/Phone |
Evia Bio Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $9.3M | 60 | 20% | N/A | N/A |
#2 | $9.1M | 59 | -34% | N/A | N/A |
#3 | $1.1M | 7 | 17% | N/A | N/A |
#4 | $0.3M | 2 | -93% | N/A | N/A |
#5 | $4.3M | 28 | 4% | N/A | N/A |
#6 | $1.4M | 9 | 50% | N/A | N/A |
#7 | $6M | 39 | 3% | N/A | N/A |
#8 | $15.8M | 102 | 7% | N/A | N/A |
#9 | $18M | 116 | 0% | $20.5M | N/A |
#10 | $34.1M | 176 | 13% | $39.1M | N/A |
What Is Evia Bio?
Evia Bio™ is a life science innovation company enabling the growing cell therapy market. We provide new non-DMSO cryopreservation solutions developed by world-leading cryobiologist, Allison Hubel, PhD. We partner with cell therapy companies looking to advance their products to clinical trials and commercialization. Our solutions unlock the full potential of emerging life-saving therapies through the use of all-natural organic compounds to protect the integrity of cells during cryopreservation and patient safety at the point of care. Please visit www.eviabio.com.
keywords:N/AN/A
Total Funding
21
Number of Employees
$1.6M
Revenue (est)
75%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.1M | 21 | -45% | N/A |
#2 | $2.1M | 21 | N/A | N/A |
#3 | $3.7M | 21 | 11% | N/A |
#4 | $1.7M | 21 | 11% | N/A |
#5 | $3M | 21 | -51% | N/A |